Building unto the success of last year, Biosimilars & Biobetters 2014 will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.
The agenda aims to bring together pharma, biotech and legal experts explaining the advantages and disadvantages within this growing market, looking at case studies from those who are developing and distributing follow on biologics with analysis of key trends in biologic pipelines, latest thinking and techniques in this growing area.
16 speakers from leading organisations will deliver innovative case-studies and presentations to include Harvest Moon Pharmaceuticals, Medimmune (AstraZeneca Biologics), Amgen, Lupin Ltd, Merck, IMS Health (UK), Fresenius Kabi Headquarters and more. Two workshops, delivered by Fresenius Kabi Headquarters and PanGenerika will also provide a detailed overview of the current regulatory situation and profitability of biosimilars and biobetters.
Keynote speakers include Catherine Akers, Regulatory Affairs Manager, Amgen, presenting on: Pharmacovigilance considerations for biologics and biosimilars, and Dr. Uwe Gudat, Head of Safety Biosimilars, Merck, who will speak on: A clinical perspective on biosimilars: development and beyond.
Latest registered attendees include: Boehringer Ingelheim, Merck Switzerland, Sanofi-Aventis SA, AbbVie, Europe Bioproducts, Takeda UK, University of Basel, Esteve SA, BD Biosciences, Univercelles plus many more.
Sponsored by Europa Bioproducts and Schwegman, Lundberg & Woessner.
For the full conference programme and further information please visit: http://www.smi-online.co.uk/2014biosimilars48.asp
Alternatively contact Fateja Begum on +44 (0)20 7827 6184 or email: fbegum@smi-online.co.uk
Sponsorship opportunities are available for this event, please contact Alia Malick on +44(0) 20 7827 6168.